Skip to main
TTRX

TTRX Stock Forecast & Price Target

TTRX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Turn Therapeutics is a clinical-stage biotechnology and medical device development company with a proprietary platform technology called PermaFusion that enhances drug performance. The company is focused on developing non-systemic, non-biologic topical immunomodulators for inflammatory skin diseases, with its lead program, GX-03, being evaluated for moderate-to-severe eczema. Turn has also secured financing through milestone-based funding and has potential for pipeline expansion and partnerships. Its focus on capital efficiency and rapid clinical translation, coupled with its proprietary technology and IP, make it an attractive investment with multiple shots on goal.

Bears say

Turn Therapeutics is a clinical-stage biotechnology and medical device development company with limited revenue potential, primarily focused on developing topical treatments for inflammatory skin diseases. Their current programs are in the early stages and are heavily reliant on ongoing clinical trials and potential partnerships for future growth. The recent financing deal may provide some financial stability, but does not guarantee immediate cash inflow and the success of their programs will depend on data generated in ongoing studies.

TTRX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Turn Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Turn Therapeutics Inc (TTRX) Forecast

Analysts have given TTRX a Strong Buy based on their latest research and market trends.

According to 1 analysts, TTRX has a Strong Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Turn Therapeutics Inc (TTRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.